Here, we found that MTSS1 expression was high in AML subsets with good prognosis (t(8;21), inv(16)), and a fraction of NK-AML, but was suppressed in AML subsets with poor outcome (FLT3-ITD). The gene discussed is FLT3; the disease is acute myeloid leukemia.